Shares last traded at $20.00 which is marginally higher than $14.97, the 50 day moving average and which is just a bit higher than the 200 day moving average of $10.21. The 50 day moving average went up by +33.63% whereas the 200 day average was up by +95.88%. Trading volume for Calithera Biosciences, Inc. was 1,212K in the last trading session. Overall, volume was up 56.56% over the stocks normal daily volume.
Traders are a little more bearish on Calithera Biosciences, Inc. recently as shown by the change in short interest. The firm experienced a rise in short interest from June 15, 2017 to May 31, 2017 of 28.73%. Short interest grew 349,332 over that period. The days to cover increased to 1.7 and the short interest percentage is 0.04% as of May 31.
Calithera Biosciences, Inc. (NASDAQ:CALA) has been the object of insider selling activity recently. Curtis Hecht, SVP, BUS. & CORP. DEVELOPMENT disclosed the sale of 700 shares of CALA stock. The shares were sold on July 6th for an average price of $18.00. Hecht now owns $286,920 of the stock according to the SEC filing. Curtis Hecht, SVP, BUS. & CORP. DEVELOPMENT sold $10,400 worth of shares at an average price of $16.00 on May 19th. That brings the SVP, BUS. & CORP. DEVELOPMENT’s holdings to $238,560 as recorded in a recent Form 4 SEC filing.
Here are some other firms who have updated their holdings. As of quarter end Creative Planning had acquired a total of 1,370 shares growing its holdings by 913.3%. The value of the investment in (CALA) increased from $2,000 to $23,000 increasing 1,050.0% quarter over quarter. As of the end of the quarter Morgan Stanley had bought 1,438 shares growing its stake by 36.0%. The value in dollars went from $13,000 to $63,000 a change of 384.6% for the reporting period.
Tower Research Capital LLC (trc) bolstered its investment by buying 1,953 shares an increase of 114.6%. Tower Research Capital LLC (trc) now controls 3,657 shares worth $42,000. The total value of its holdings increased 600.0%. Goldman Sachs Group Inc added to its stake by buying 117,832 shares an increase of 729.7% from 12/31/2016 to 03/31/2017. Goldman Sachs Group Inc claims 133,981 shares with a value of $1,547,000. The value of the position overall is up by 2,875.0%.
March 9 investment analysts at JMP Securities left the company rating at “Market Outperform” and moved down the price target from $20.00 to $12.00. Citigroup added CALA to its research portfolio with a rating of “Buy” and projecting a price target of $11.00.
On January 28 Citigroup maintained a company rating of “Buy” and raised the price expectation to $30.00 from $15.00. On October 27, 2014 Wells Fargo started covering CALA setting a rating of “Outperform”.
Equity analyst Citigroup starting coverage on CALA by announcing an initial rating of “Buy” and setting a price target of $15.00. On October 27 analysts at JMP Securities initiated coverage on the stock giving it an initial rating of “Market Outperform” and price target of $20.00.
The company is trading up by 11.11 percent from yesterday’s close. In the last earnings report the EPS was $-1.60 and is projected to be $-0.85 for the current year with 35,294,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.21 with next year’s EPS anticipated to be $-0.96.
Calithera Biosciences, Inc., launched on March 9, 2010, is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The Company is involved in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Business’s lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase..